The Food and Drug Administration’s draft guidance on blood glucose monitoring test systems for prescription point-of-care use would appropriately improve the safety and efficacy of the devices while recognizing their vital role in hospitals and health systems, AHA said in comments submitted yesterday. “Blood glucose testing remains one of the most commonly performed initial diagnostic screening tests in the acute and post-acute care settings, and ensuring safe and effective use of these devices is essential,” AHA wrote. “…If finalized, this guidance would provide automatic Clinical Laboratory Improvement Act waiver status to BGMS for POC use, eliminating the previous requirements under ‘high complexity’ testing and, ultimately, benefiting the patients for whom we care.” With respect to disinfectant products for BGMS, AHA urged FDA to consider compiling a finite list of universally acceptable disinfectant products that would apply to all medical devices or classes of device. “This commonsense approach will limit waste and confusion and decrease the potential for hospital staff to apply the improper disinfectant to a specific device,” the association said.

Related News Articles

Headline
The House Energy and Commerce Committee held a markup April 29 where it advanced the AHA-supported SUPPORT Act (H.R. 2483). The legislation would reauthorize…
Perspective
Public
Just 16 days from now, more than 1,000 hospital and health system leaders from across the country will arrive in Washington, D.C., for the 2025 AHA Annual…
Headline
The Centers for Medicare & Medicaid Services today released a notice seeking public comment on the collection of information request regarding the State…
Chairperson's File
Public
This is an incredibly dynamic and transformative time for health care. One resource I have found incredibly helpful in speaking with many of you and engaging…
Perspective
Public
Congressional lawmakers are heading home for a two-week district work period after both the Senate and House passed a revised budget resolution for fiscal year…
Headline
The Trump administration yesterday released executive orders on reducing anti-competitive regulatory barriers and repealing certain regulations deemed unlawful…